TABLE 1.
Patient Characteristics
| Enrolled patients, No. | 37 |
|---|---|
| Age, y | |
| Median | 65 |
| Range | 47-82 |
| Sex | |
| Men | 15 |
| Women | 22 |
| Race/ethnicity | |
| White | 32 |
| African American | 5 |
| Hispanic/Latino | 0 |
| ECOG performance status | |
| 0 | 23 |
| 1 | 13 |
| 2 | 1 |
| Stage | |
| IVA | 14 |
| IVB | 23 |
| Recurrent | 8 |
| Histology | |
| Adenocarcinoma | 26 |
| Adenosquamous | 2 |
| Squamous | 2 |
| Bronchioloalveolar | 1 |
| NSC NOS | 6 |
| Molecular Abnormality | |
| KRAS mutation only | 14 |
| EGFR-amplified only | 10 |
| EGFR mutant only | 1 |
| KRAS mutation + EGFR amplification | 6 |
| EGFR mutation + EGFR amplification | 2 |
| BRAF mutation + EGFR amplification | 4 |
| Prior anticancer therapies | |
| Targeted agents | 3 |
| Chemotherapy (adjuvant) | 4 |
| Surgery | 13 |
| Thoracic surgery for NSCLC | 9 |
| Resection of brain metastasis | 4 |
| Radiation | 15 |
| Adjuvant (mediastinum) | 5 |
| Palliative | 12 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NSC, non–small cell; NSCLC, non–small cell lung cancer.